US Patent

US8158616 — Azetidine and cyclobutane derivatives as JAK inhibitors

Composition of Matter · Assigned to Incyte Corp · Expires 2032-05-31 · 6y remaining

Vulnerability score 4/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects azetidine and cyclobutane derivatives that inhibit JAK, which are useful in treating JAK-associated diseases.

USPTO Abstract

The present invention relates to azetidine and cyclobutane derivatives, as well as their compositions, methods of use, and processes for preparation, which are JAK inhibitors useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

Drugs covered by this patent

Patent Metadata

Patent number
US8158616
Jurisdiction
US
Classification
Composition of Matter
Expires
2032-05-31
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Incyte Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.